Cover Image
市場調查報告書

PharmaPoint:精神分裂症 - 現在/未來的主要企業

PharmaPoint: Schizophrenia - Current and Future Players

出版商 GlobalData 商品編碼 299716
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:精神分裂症 - 現在/未來的主要企業 PharmaPoint: Schizophrenia - Current and Future Players
出版日期: 2014年02月28日 內容資訊: 英文 40 Pages
簡介

本報告提供急速成長的精神分裂症治療藥市場相關資料研究,以包含新加入廠商的競爭情形為焦點,再加上主要企業相關最新資訊詳細的分析,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 市場預測

  • 全球市場
    • 預測
    • 推動因素·障礙

第4章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Janssen Pharmaceuticals
    • Eli Lilly and Company
    • Roche
    • Alkermes
    • EnVivo Pharmaceuticals

第5章 附錄

圖表

目錄
Product Code: GDHC1030FPR

GlobalData has released its pharma report, "PharmaPoint: Schizophrenia - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Schizophrenia Market. The report identifies and analyses the key companies shaping and driving the global Schizophrenia market. The report provides insight into the competitive Schizophrenia landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Schizophrenia
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of the Schizophrenia sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving the Schizophrenia Market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Schizophrenia market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Global Drivers and Barriers

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Janssen Pharmaceuticals
    • 4.3.2. Eli Lilly and Company
    • 4.3.3. Roche
    • 4.3.4. Alkermes
    • 4.3.5. EnVivo Pharmaceuticals

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Diagnosis and Treatment Rates
    • 5.4.2. Adherence Rates
    • 5.4.3. General Pricing Assumptions
    • 5.4.4. Generic Erosion
  • 5.5. Key Opinion Leaders
  • 5.6. About the Authors
    • 5.6.1. Author
    • 5.6.2. Reviewers
    • 5.6.3. Global Head of Healthcare
  • 5.7. About GlobalData
  • 5.8. Disclaimer

List of Tables

  • Table 1: Global Sales Forecast ($m) for Schizophrenia, 2012-2022
  • Table 2: Global Schizophrenia Market, Drivers and Barriers, 2012-2022
  • Table 3: Janssen Schizophrenia Portfolio Assessment, 2014
  • Table 4: Janssen SWOT Analysis, 2014
  • Table 5: Eli Lilly Schizophrenia Portfolio Assessment, 2014
  • Table 6: Eli Lilly SWOT Analysis, 2014
  • Table 7: Roche Schizophrenia Portfolio Assessment, 2014
  • Table 8: Roche SWOT Analysis, 2014
  • Table 9: Alkermes Schizophrenia Portfolio Assessment, 2014
  • Table 10: Alkermes SWOT Analysis, 2014
  • Table 11: EnVivo Schizophrenia Portfolio Assessment, 2014
  • Table 12: EnVivo Pharmaceuticals SWOT Analysis, 2014

List of Figures

  • Figure 1: Global Schizophrenia Drug Sales by Region, 2012-2022
  • Figure 2: Schizophrenia Therapeutics - Pipeline by Company, 2014
Back to Top